Takashi Okuda represents life sciences and technology companies in high-stakes patent disputes. He has experience in both bench and jury trials and translates complex scientific and technical concepts into clear, persuasive cases.

Takashi has extensive IP litigation experience across multiple forums and sectors. He guides multinational companies through every stage of patent disputes, from early investigation and case strategy through trial. He also represents clients in inter partes review (IPR) proceedings before the Patent Trial and Appeal Board.

Fluent in Japanese, Takashi also regularly advises Japanese companies. He works directly with in-house teams and technical personnel to help navigate the US patent litigation system.

Takashi’s experience at and prior to joining Latham includes representing:

  • Merck Sharp & Dohme in Hatch-Waxman litigations relating to antiviral drug for CMV
  • Ascendis in ITC investigation relating to achondroplasia drug
  • Biogen and Alkermes in Hatch-Waxman litigations relating to multiple sclerosis drug
  • Philip Morris & Altria in district court litigation relating to e-vapor technologies, securing jury trial win
  • BASF in district court litigation relating to omega-3 fatty acids, obtaining favorable jury trial outcome in patent infringement suit involving 17 patents 
  • Ricoh in district court litigation relating to semiconductor technology, obtaining favorable settlement 
  • Takeda in numerous Hatch-Waxman litigations relating to its blockbuster anti-ulcer drug
  • Santen Pharmaceutical, Asahi Glass, and Oak Pharmaceuticals in Hatch-Waxman litigations and IPR proceeding relating to glaucoma drugs, obtaining favorable final decision upholding validity

Bar Qualification

  • New York

Education

  • JD, Boston College Law School
  • LLB, Keio University